

August 25, 2017  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

**Completion of Payment for Subscription for the 42nd Stock Acquisition Rights  
by Third-Party Allotment**

TOKYO, Japan, August 25, 2017 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo) announced that payment of ¥32,560,000 has been completed today for the subscription for the 42nd stock acquisition rights by third-party allotment resolved at its board of directors' meeting on August 9, 2017.

Summary of the 42nd stock acquisition rights

Date of allotment	August 25, 2017
Number of stock acquisition rights issued	88,000 units
Issue price	¥370 per stock acquisition right (total of ¥32,560,000)
Number of residual securities from the issuance	Number of residual securities: 8,800,000 shares There is no maximum exercise price. The minimum exercise price is ¥108, but even at the minimum exercise price, the number of residual securities is 8,800,000 shares.
Amount of funding	¥1,909,560,000 (Estimated net proceeds)
Exercise price and exercise price amendment provisions	Initial exercise price: ¥215 On February 26, 2018, the exercise price shall be amended to an amount equivalent to 90% of the closing price of SymBio's common shares on February 23, 2018, but in the event that the price is below the minimum exercise price, the minimum exercise price shall be the exercise price after amendment. The warrants are not classified as an MSCB, etc. as defined in Rule 410, Paragraph 1 of the Securities Listing Regulations set forth by the Tokyo Stock Exchange.
Method for subscription or allotment	The rights shall be allotted by third-party allotment.
Entity for the allotment	SBI SECURITIES Co., Ltd.
Exercise period of the warrants	From August 26, 2017 to August 27, 2018

(Note) For further details, please refer to the press release dated August 9, 2017, "Notice of the Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment".

Note: This document does not constitute an investment solicitation for any securities for sale. This document has been prepared to publicly announce matters related to the issuance of the 42nd stock acquisition rights, and not for the purpose of soliciting investment. This document does not constitute an offer of investment in nor solicitation for purchase of the 42nd stock acquisition rights within the United States. Regarding the 42nd stock acquisition rights, SymBio has not registered, and is not scheduled to register, any of them under the United States Securities Act of 1933. The securities may not be offered or sold in the United States without a registration or an exemption from registration under the United States Securities Act of 1933. No offer of securities in the United States will be made in connection with this transaction.



**[Contact]**

Investor Relations

Tel: +81(0)3 5472 1125

**About Symbio Pharmaceuticals Limited**

Symbio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called Symbio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.

Note: This document does not constitute an investment solicitation for any securities for sale. This document has been prepared to publicly announce matters related to the issuance of the 42nd stock acquisition rights, and not for the purpose of soliciting investment. This document does not constitute an offer of investment in nor solicitation for purchase of the 42nd stock acquisition rights within the United States. Regarding the 42nd stock acquisition rights, Symbio has not registered, and is not scheduled to register, any of them under the United States Securities Act of 1933. The securities may not be offered or sold in the United States without a registration or an exemption from registration under the United States Securities Act of 1933. No offer of securities in the United States will be made in connection with this transaction.